Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer.

Bolun ZhouFan ZhangWei GuoShuhang WangNing LiBin QiuLiang ZhaoJian LiKang ShaoQi XueFang LvShugeng Gao

Published in: Journal for immunotherapy of cancer (2024)

These updated analyses were the first to unveil the 5-year survival benefits of neoadjuvant sintilimab monotherapy, implying the potential value of PD-1 inhibitors in neoadjuvant therapy.

Keyphrases

rectal cancer
locally advanced
lymph node
squamous cell carcinoma
radiation therapy
randomized controlled trial
clinical trial
combination therapy
risk assessment
human health
climate change